SupadElixir Co., Ltd. announced on the 20th that
it will enter the cosmetics business based on peptide application technology. The
company is about to introduce five products of HAHN’S PEPTIDE, derma cosmetics
brand. The five products
passed the primary irritation test through 24-hour skin patch and were
proven for their safety and reliability. “HAHN’S PEPTIDE’s five new products
will be introduced by this fall. We
are in contact with distributors such as home shopping network and offline
vendors in various ways to promote sales,” said a company official.
SupadElixir is a venture company developing peptides and new protein
drugs, founded by professor Han Jang-hee at Kangwon National University School
of Medicine in 2009.
He registered a US patent in the field of anti-aging with Dr.
Chalfie based on the results of the research that he conducted as a
postdoctoral researcher at the lab of Dr. Marty Chalfie, who is the 2008 Nobel
Prize laureate in chemistry.
Since appointed to the Kangwon National University in 1997,
he has devoted himself to the research of anti-aging and
anti-inflammatory peptide for more than two decades.
Peptide is the protein fragments composed of 2-50 amino
acids. SupadElixir focuses on developing small peptides with small molecular
that are composed of 3-4 amino acids. These peptides are safe as they are
derived from human proteins, and have excellent functionality as they were
selected by efficacy tests. They are excellent biomaterials,
which are very stable even under severe conditions and have a lot of advantages
company explains one of the greatest advantages of their products is usability; thanks to the high skin penetration rate, peptides are delivered to the dermis layer of the skin just by
applying products without having to use an additional device.
SupadElixir has so far developed more than 50 peptides.
Among them, SE101 peptide has an excellent
inhibitory effect on inflammation and new blood vessel
formation so is currently developed as a new drug material effective for
various inflammation-related diseases. The company plans to develop SE105 as an
alternate new drug material for insulin that activates glucose uptake in muscle
cells and fat cells, regulating glucose metabolism.